Performance of pacemaker leads in alternative lead positions after tricuspid valve replacement.


Journal

Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944

Informations de publication

Date de publication:
11 2020
Historique:
received: 03 04 2020
revised: 30 09 2020
accepted: 11 10 2020
pubmed: 16 10 2020
medline: 14 10 2021
entrez: 15 10 2020
Statut: ppublish

Résumé

Bradycardic arrhythmias requiring pacemaker (PM) implantation are still common in patients in need of tricuspid valve replacement (TVR). Leaving an existing PM lead in an extravalvular position may represent a helpful alternative in special situations like the implantation of a mechanical TV. This study aimed to examine the short- to mid-term outcome of paravalvular leads concerning lead survival and prosthesis dysfunction in patients after TVR. A retrospective case-control study of patients with TVR and ventricular pacing was conducted. Patients from the database of the Leipzig Heart Center were included. Data of the paravalvular lead group (PVG) and coronary sinus lead group (CSG) were compared to a control group with conventional transvalvular leads (TVG). Eighty patients with TVR and cardiac PM (TVG [n = 13], PVG [n = 40], and CSG [n = 27]) were included. The mean follow-up was 2.8 years. The rate of lead revisions (TVG 15.4%, PVG 2.5%, and CSG 7.5%) was lower in PVG but without significance (P = .286). The CSG demonstrated significantly higher pacing thresholds (1.4 V/0.8 ms) than TVG (0.5 V/0.4 ms), P = .004. However, the deterioration of threshold amplitudes during follow-up was similar in CSG (7.4%) and PVG (7.5%) compared with controls (7.7%). Function of TV prosthesis regarding development of stenosis or regurgitation showed a similarity between the groups (regurgitation PVG P = .692, CSG P = 1; stenosis PVG P = .586, CSG P = 0.69). Paravalvular positioning of PM leads seems to represent a reasonable alternative to the conventional transvalvular lead positioning concerning the lead and Tricuspid Valve prosthesis's function and durability in selected patients.

Sections du résumé

BACKGROUND
Bradycardic arrhythmias requiring pacemaker (PM) implantation are still common in patients in need of tricuspid valve replacement (TVR). Leaving an existing PM lead in an extravalvular position may represent a helpful alternative in special situations like the implantation of a mechanical TV. This study aimed to examine the short- to mid-term outcome of paravalvular leads concerning lead survival and prosthesis dysfunction in patients after TVR.
METHODS
A retrospective case-control study of patients with TVR and ventricular pacing was conducted. Patients from the database of the Leipzig Heart Center were included. Data of the paravalvular lead group (PVG) and coronary sinus lead group (CSG) were compared to a control group with conventional transvalvular leads (TVG).
RESULTS
Eighty patients with TVR and cardiac PM (TVG [n = 13], PVG [n = 40], and CSG [n = 27]) were included. The mean follow-up was 2.8 years. The rate of lead revisions (TVG 15.4%, PVG 2.5%, and CSG 7.5%) was lower in PVG but without significance (P = .286). The CSG demonstrated significantly higher pacing thresholds (1.4 V/0.8 ms) than TVG (0.5 V/0.4 ms), P = .004. However, the deterioration of threshold amplitudes during follow-up was similar in CSG (7.4%) and PVG (7.5%) compared with controls (7.7%). Function of TV prosthesis regarding development of stenosis or regurgitation showed a similarity between the groups (regurgitation PVG P = .692, CSG P = 1; stenosis PVG P = .586, CSG P = 0.69).
CONCLUSION
Paravalvular positioning of PM leads seems to represent a reasonable alternative to the conventional transvalvular lead positioning concerning the lead and Tricuspid Valve prosthesis's function and durability in selected patients.

Identifiants

pubmed: 33058294
doi: 10.1111/pace.14093
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1382-1389

Informations de copyright

© 2020 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals LLC.

Références

Lin G, Nishimura RA, Connolly HM, Dearani JA, Sundt TM, Hayes DL. Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. J Am Coll Cardiol. 2005;45:1672-1675.
Aris A, Callejo F, Cobiella J, Maestre M. Tricuspid valve replacement in the presence of an endocardial pacemaker electrode. J Heart Valve Dis. 2004;13:523-524.
Yoshikai M, Miho T, Satoh H, Nakanishi H. Tricuspid valve replacement preserving endocardial pacemaker lead. J Card Surg. 2016;31:311-314.
Martins RP, Galand V, Leclercq C, Daubert J-C. Cardiac electronic implantable devices after tricuspid valve surgery. Heart Rhythm. 2018;15:1081-1088.
Klutstein M, Balkin J, Butnaru A, Ilan M, Lahad A, Rosenmann D. Tricuspid incompetence following permanent pacemaker implantation. Pacing Clin Electrophysiol. 2009;32:S135-S137.
Saran N, Said SM, Schaff HV, et al. Outcome of tricuspid valve surgery in the presence of permanent pacemaker. J Thorac Cardiovasc Surg. 2018;155:1498-1508.
Dokainish H, Elbarasi E, Masiero S, et al. Prospective study of tricuspid valve regurgitation associated with permanent leads in patients undergoing cardiac rhythm device implantation: background, rationale, and design. Glob Cardiol Sci Pract. 2015;2015:41.
Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol. 2017;69:2331-2341.
Kerwin SA, Mayotte MJ, Gornick CC. Transcatheter pacemaker implantation in a patient with a bioprosthetic tricuspid valve. J Interv Card Electrophysiol. 2015;44:89-90.
Noheria A, van Zyl M, Scott LR, et al. Single-site ventricular pacing via the coronary sinus in patients with tricuspid valve disease. EP Eur. 2018;20:636-642.
Peng H, Sun Z, Zhang H, Ma W. Long-term performance of right ventricular pacing leads: risk factors associated with permanent right ventricular pacing threshold increase. J Interv Card Electrophysiol. 2019;55:349-357.
McLeod CJ, Jost CHA, Warnes CA, et al. Epicardial versus endocardial permanent pacing in adults with congenital heart disease. J Interv Card Electrophysiol. 2010;28:235-243.
Eleid MF, Blauwet LA, Cha Y-M, et al. Bioprosthetic tricuspid valve regurgitation associated with pacemaker or defibrillator lead implantation. J Am Coll Cardiol. 2012;59:813-818.
Esperer HD, Mahmoud FO, von der Emde J. Is epicardial dual chamber pacing a realistic alternative to endocardial DDD pacing? Initial results of a prospective study. Pacing Clin Electrophysiol. 1992;15:155-161.
Molina JE, Roberts CL, Benditt DG. Long-term follow-up of permanent transvenous pacing systems preserved during tricuspid valve replacement. Ann Thorac Surg. 2010;89:318-320.
Paech C, Wagner F, Karthe B, Bakthiary F, Gebauer RA. A novel technique for lead sparing tricuspid valve replacement in the case of a transvenous ICD lead. Clin Case Rep. 2018;6:1588-1591.
Chang B-C, Lim S-H, Yi G, et al. Long-term clinical results of tricuspid valve replacement. Ann Thorac Surg. 2006;81:1317-1324.

Auteurs

Anna Michaelis (A)

Department for Pediatric Cardiology, University of Leipzig-Heart Center, Leipzig, Germany.

Franziska Wagner (F)

Department for Pediatric Cardiology, University of Leipzig-Heart Center, Leipzig, Germany.

Frank-Thomas Riede (FT)

Department for Pediatric Cardiology, University of Leipzig-Heart Center, Leipzig, Germany.

Thomas Schroeter (T)

Department for Cardiac Surgery, University of Leipzig-Heart Center, Leipzig, Germany.

Ingo Daehnert (I)

Department for Pediatric Cardiology, University of Leipzig-Heart Center, Leipzig, Germany.

Bettina Pfannmueller (B)

Department for Cardiac Surgery, University of Leipzig-Heart Center, Leipzig, Germany.

Roman Antonin Gebauer (RA)

Department for Pediatric Cardiology, University of Leipzig-Heart Center, Leipzig, Germany.

Christian Paech (C)

Department for Pediatric Cardiology, University of Leipzig-Heart Center, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH